# Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

> **NCT02730871** · PHASE4 · TERMINATED · sponsor: **Alcon Research** · enrollment: 173 (actual)

## Conditions studied

- Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
- **DRUG:** Brinzolamide/brimonidine vehicle
- **DRUG:** Travoprost 0.004%/timolol 0.5% solution

## Key facts

- **NCT ID:** NCT02730871
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-24
- **Primary completion:** 2018-07-13
- **Final completion:** 2018-07-13
- **Target enrollment:** 173 (ACTUAL)
- **Why stopped:** Enrollment Challenges
- **Last updated:** 2019-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02730871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02730871, "Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02730871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*